Antibody-drug conjugate
Intravesical Enfortumab Vedotin for Bladder Cancer
Recruiting1 awardPhase 1
Baltimore, Maryland
This trial tests a new treatment for bladder cancer by delivering the drug directly into the bladder through a thin tube. The study will determine the best dose and evaluate its effectiveness and side effects.
Monoclonal Antibodies
Atezolizumab + Cisplatin + Gemcitabine for Bladder Cancer
Recruiting3 awardsPhase 1 & 2
Hartford, Connecticut
This trial is testing whether adding atezolizumab to gemcitabine and cisplatin chemotherapy is safe and whether it works better than gemcitabine and cisplatin alone for treating pancreatic cancer.
Anti-metabolites
Gemcitabine + Docetaxel for Bladder Cancer
Recruiting1 awardPhase 2
Gainesville, Florida
"This trial aims to study the effectiveness and patient compliance of using a combination of gemcitabine and docetaxel to treat low-grade intermediate-risk bladder cancer. Bladder cancer is common in the
Popular Filters
Trials for Urothelial Carcinoma Patients
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Antibody-Drug Conjugate
Enfortumab Vedotin for Bladder Cancer
Recruiting1 awardPhase 1 & 2
Anchorage, Alaska
This trial is testing a new drug called enfortumab vedotin alone and with other treatments in patients with advanced or muscle-invasive bladder cancer. The goal is to see how well these treatments work and what side effects they might have. Enfortumab vedotin targets and kills cancer cells, while pembrolizumab helps the immune system fight the cancer.
Pembrolizumab for Bladder Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial looks at how well pembrolizumab works in treating patients with muscle-invasive bladder cancer or locally advanced urothelial cancer. Monoclonal antibodies that block the PD-1 axis can interfere with the ability of tumor cells to grow.
mTOR inhibitor
Sapanisertib for Bladder Cancer
Recruiting1 awardPhase 2
Los Angeles, California
This trial studies how well sapanisertib works in treating patients with advanced or metastatic bladder cancer that have specific genetic mutations. Sapanisertib is taken by mouth and aims to stop cancer cell growth by blocking necessary enzymes.
Inhibitor
Pemigatinib for Bladder Cancer
Recruiting2 awardsPhase 2
Baltimore, Maryland
This trial tests how well Pemigatinib, a pill that blocks proteins helping cancer grow, works in patients with bladder cancer that has come back after previous treatment. The drug aims to stop specific proteins needed for cancer growth.
Trials for Breast Cancer Patients
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
Trials for Metastatic Patients
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Immunotherapy
Durvalumab + Olaparib for Bladder Cancer
Recruiting0 awardsPhase 2
Birmingham, Alabama
This trial tests a combination of two drugs, durvalumab and olaparib, for patients with advanced bladder cancer who can't receive standard chemotherapy. Durvalumab helps the immune system attack cancer, while olaparib makes it harder for cancer cells to repair themselves. The goal is to see if this combination is more effective than using durvalumab alone.
Antibody-Drug Conjugate
Enfortumab Vedotin for Bladder Cancer
Recruiting1 awardPhase 1 & 2
Anchorage, Alaska
This trial is testing a new drug called enfortumab vedotin alone and with other treatments in patients with advanced or muscle-invasive bladder cancer. The goal is to see how well these treatments work and what side effects they might have. Enfortumab vedotin targets and kills cancer cells, while pembrolizumab helps the immune system fight the cancer.
Kinase Inhibitor
LOXO-435 for Bladder Cancer
Recruiting1 awardPhase 1
Nashville, Tennessee
This trial is testing LOXO-435, a new drug, to see if it can help treat advanced cancers with a specific genetic change. It aims to block a gene that helps cancer cells grow. The study will check the drug's safety and effectiveness in these patients. LOX may be a potential effective therapeutic target to treat colorectal cancer.
Phase 3 Trials
Monoclonal Antibodies
TAR-200 + Cetrelimab vs Chemoradiotherapy for Bladder Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing a new treatment for bladder cancer that combines a device delivering medication directly to the bladder with a drug that helps the immune system fight cancer. The goal is to see if this combination works better than the usual treatment in keeping the bladder free from cancer events.
Alkylating agents
Pembrolizumab + Chemoradiotherapy for Bladder Cancer
Recruiting1 awardPhase 3
Washington, District of Columbia
This trial will compare the effectiveness of a new cancer treatment (pembrolizumab + chemoradiotherapy) to the current standard of care (chemoradiotherapy alone) for people with muscle-invasive bladder cancer.
Chemotherapy
Chemotherapy + Nivolumab for Bladder Cancer
Recruiting2 awardsPhase 3
Tucson, Arizona
This trial will compare the efficacy of nivolumab plus neoadjuvant gemcitabine/cisplatin chemotherapy followed by post-surgery continuation of immuno-oncology therapy versus neoadjuvant gemcitabine/cisplatin chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer.
Anti-tumor antibiotic
Immunotherapy + Chemotherapy for Bladder Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is studying if adding the drugs durvalumab and tremelimumab to standard chemotherapy can help to control transitional cell carcinoma of the urothelium that has spread to other parts of the body and cannot be removed by surgery.
Immunotherapy
N-803 + BCG for Bladder Cancer
Recruiting1 awardPhase 2 & 3
Anchorage, Alaska
This trial is testing a new drug, N-803, for people with bladder cancer that has not responded to BCG treatment. Patients will receive the new drug through a urinary catheter weekly for 6 weeks, followed by maintenance treatment every 3 or 6 weeks for up to 3 years.
Pembrolizumab for Bladder Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial looks at how well pembrolizumab works in treating patients with muscle-invasive bladder cancer or locally advanced urothelial cancer. Monoclonal antibodies that block the PD-1 axis can interfere with the ability of tumor cells to grow.
Trials With No Placebo
Monoclonal Antibodies
TAR-200 + Cetrelimab vs Chemoradiotherapy for Bladder Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing a new treatment for bladder cancer that combines a device delivering medication directly to the bladder with a drug that helps the immune system fight cancer. The goal is to see if this combination works better than the usual treatment in keeping the bladder free from cancer events.
Monoclonal Antibodies
TAR-200 + Cetrelimab for Bladder Cancer
Recruiting1 awardPhase 2
Tucson, Arizona
This trial is testing a drug-delivery device (TAR-200) and an immune-boosting drug (cetrelimab) in bladder cancer patients who have not responded well to other treatments. TAR-200 releases medicine directly into the bladder, while cetrelimab helps the immune system fight cancer. Cetrelimab is being studied in patients with different types of bladder cancer.
Monoclonal Antibodies
SGN-B6A for Cancer
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing a new drug called sigvotatug vedotin alone and with other treatments to see if it is safe and effective for people with solid tumors. It will also check for any side effects. The study includes different parts to determine the best dose and to see how well the drug works alone and in combination with other treatments.
Enhanced MRI for Bladder Cancer Staging
Recruiting1 awardPhase < 1
Pittsburgh, Pennsylvania
This trial is testing a new way to use MRI to look for bladder cancer. A contrast agent is used to help better visualize the tumor. The MRI images are then reviewed by two radiologists to determine the stage of the cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.